|
|
Volumn 92, Issue 8, 2005, Pages 1588-1590
|
|
Can a rational design for metronomic chemotherapy dosing be devised?
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
ESTRAMUSTINE;
TAXANE DERIVATIVE;
TEMOZOLOMIDE;
ANIMAL MODEL;
BONE MARROW SUPPRESSION;
CANCER CELL;
CANCER CHEMOTHERAPY;
CELL GROWTH;
CELL PROLIFERATION;
DOSE RESPONSE;
DRUG DOSE REGIMEN;
ENDOTHELIUM CELL;
FIBROBLAST;
GROWTH INHIBITION;
HEMATOPOIETIC STEM CELL;
HUMAN;
HUMAN CELL;
KIDNEY CARCINOMA;
LETTER;
MAXIMUM TOLERATED DOSE;
MELANOMA CELL;
METRONOMIC DOSE;
NONHUMAN;
OVARY CANCER;
PRIORITY JOURNAL;
SOLID TUMOR;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
NEOPLASMS;
RESEARCH DESIGN;
|
|
EID: 18944379083
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bjc.6602474 Document Type: Letter |
|
Times cited : (16)
|
|
References (4)
|
